Picture EBD Group BioPharm America 2018 Boston Speakers 600x60px
Document › Details

Advion, Inc.. (12/1/14). "Press Release: LESA Technology to be Studied in Real-time Surgical Guidance". Ithaca, NY.

Region Region Boston, MA
  Country United States (USA)
Organisations Organisation Advion Inc.
  Group Bohui (Group)
  Organisation 2 Brigham and Women’s Hospital (BWH)
  Group Partners HealthCare System (Group)
Products Product TriVersa™ NanoMate® system
  Product 2 LESA sample analysis system (Liquid Extraction Surface Analysis) (Advion)
Persons Person Henion, Jack (Advion 200603– CSO before CEO + 1993 co-founder of Advion)
  Person 2 Lummus, Amy (formerly Boardman) (Advion 200708 MarCom Manager)

Advion, Inc. announces that its TriVersa NanoMate with liquid extraction surface analysis (LESA) capability will be evaluated as part of a study at Brigham and Women’s Hospital.

When coupled to a mass spectrometer, the TriVersa NanoMate with LESA capability allows for automated and direct sample analysis from samples with minimal sample preparation. The user can select tissue samples around the interest area, and get real-time mass spectral data.

Dr. Nathalie Agar, Director of the Surgical Molecular Imaging Laboratory in the Department of Neurosurgery at BWH, will work with tissue preparations for biomarker analysis to guide real-time surgical margin decisions in the operating room with a comparison to alternative modern techniques as well as traditional pathology. The purpose of the study is to determine novel markers for cancer tissue, detect them using LESA and mass spectrometry, and then guide precise and accurate surgery marginal incision start and stop points. If successful, this could increase treatment success, decrease residual cancer presence and minimize unnecessary removal of healthy tissue.

According to Advion Chief Scientific Officer, Jack Henion, PhD, “This is an exciting aspect of translational research for cancer biomarkers that potentially has immediate benefit for patients undergoing cancer surgery. In the intended workflow from ‘bench-to-bedside’ (or more accurately from ‘bench-to-operation room’) a surgical decision is guided not only by standard procedures but additionally by mass spectrometry data from tissue samples obtained in real-time during the procedure.”

Pilot experiments are now underway with an initial publication targeted for early 2015.

About Advion, Inc.

Advion develops, manufactures and globally supports mass spectrometers, chip-based ion sources, microfluidic flow chemistry systems and consumables for life science and related industries. We seek to enhance analysis performance and workflows. Using our deep scientific and engineering knowledge of mass spectrometry and microfludics, we leverage our passionate employees’ commitment to create quality, flexible and fit-for-purpose solutions. More about Advion, Inc. can be found on our website,

For Advion, Inc.

Amy Lummus
Director of Marketing
Advion, Inc.
Telephone: 1.607.379.4565

Record changed: 2015-02-21


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Bohui (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group BioPharm America 2018 Boston September 600x60px

» top